CAMBRIDGE, Massachusetts, August 14, 2026, 10:53 EDT — Moderna Inc. NASDAQ:MRNA secured regulatory clearance for its pioneering mRNA-based flu vaccine in the United States, but analysts expect the new product will not make a significant impact on revenue until late 2027, positioning the breakthrough as a challenge for the company’s cash management.
The split is significant as Moderna’s expenditures continue to exceed its revenue. Regulatory approval affirms the platform’s value beyond COVID-19, but it does not resolve short-term financial results.
At 10:01 EDT on Friday, shares were at $62.67, a decrease of 1.5%. The previous session closed at $63.65. Despite the approval, the stock continued to trade above the most recent average analyst target.
| Market measure | Value | Investor reading |
|---|---|---|
| Friday price, 10:01 EDT | $62.67 | Falls 1.5% in early trade |
| Thursday close | $63.65 | Short-term approval premium still present |
| 52-week range | $22.28–$85.60 | Significant event-based swings |
| Average analyst target | $49.37 | Roughly 21% below Friday’s price |
The FDA has given full approval to mFLUSIVA for people between the ages of 50 and 64. Those aged 65 and above have been granted accelerated approval. Moderna is required to conduct an additional trial to verify the benefit in the older age group.
| mFLUSIVA item | Verified status | What investors should watch |
|---|---|---|
| Ages 50–64 | Fully approved | Sales trends and price strategies |
| Ages 65+ | Conditional approval | Progress on required studies |
| Pivotal trial | Includes over 40,000 adults | Effectiveness outside trials |
| Relative efficacy | 26.6% higher than standard-dose vaccine | How it competes with current vaccines |
The trial outcome provides Moderna with a tangible marketing advantage. Its vaccine demonstrated 26.6% greater effectiveness compared to a licensed standard-dose vaccine. Another study indicated it produced higher antibody responses in seniors than Sanofi SA’s EPA:SAN high-dose shot.
Messenger RNA allows for faster manufacturing adjustments when strains shift in circulation. This could enhance the accuracy of strain alignment. Leading competitors retain strong contractual relationships, among them GSK plc LON:GSK, CSL Ltd. ASX:CSL, and AstraZeneca plc LON:AZN.
| Commercial milestone | Timing | Financial significance |
|---|---|---|
| FDA approval | August 5, 2026 | Confirms platform |
| 2026 U.S. contracting cycle | Already missed | Restricts short-term sales |
| Meaningful revenue anticipated | Second half of 2027 | Cash outflow remains main factor initially |
| Jefferies U.S. sales forecast | $750 million by 2030 | Covers flu and future COVID-flu product |
Timing of the contract remains a constraint. Reuters noted that Moderna did not participate in the 2026 U.S. purchasing cycle. As a result, analysts anticipate minimal significant mFLUSIVA revenue until late 2027.
The balance sheet offers some respite, though not unlimited flexibility. At the end of June, Moderna held $6.9 billion in cash and investments. In July, it paid $950 million as part of a litigation settlement.
| Q2 2026 measure | Reported value | Change or context |
|---|---|---|
| Revenue | $145 million | $142 million was reported for the previous year |
| Net loss | $782 million | Narrowed 5% from the previous year |
| R&D expense | $651 million | Decreased by 7% |
| Cash and investments | $6.9 billion | Declined from $7.5 billion at the end of Q1 |
| Year-end cash outlook | $4.7–$5.2 billion | Increased by approximately $200 million |
Chief Executive Stéphane Bancel said the quarter improved Moderna’s financial position, citing a more favourable operating-expense outlook. The figures remain striking. Research expenditures exceeded quarterly revenue by more than four times.
| Analyst recommendation | Count | Share of 23 ratings |
|---|---|---|
| Buy | 4 | 17% |
| Hold | 16 | 70% |
| Sell | 3 | 13% |
| Average target | $49.37 | Range: $25–$79 |
Opinions vary on Wall Street. Goldman Sachs has set a $67 price target, whereas Wolfe Research’s target is $25. The divergence highlights contrasting perspectives regarding pipeline valuation, vaccine demand, and the rate of cash burn.
Risks: Adoption could be influenced by CDC guidance and coverage decisions by insurers. The label might be updated following results from the confirmatory senior trial. Factors such as competing products, vaccine hesitancy, delays in contracting, and ongoing operational losses could reduce anticipated returns.
Moderna’s platform receives a boost with the approval. However, the financial outcome relies on effective delivery. In the absence of orders, conserving cash outweighs the importance of the scientific milestone.
